Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03).
Erica L MayerChristian FeslDominik HlauschekLaura Garcia-EstevezHarold J BursteinNicholas ZdenkowskiViktor WetteKathy D MillerMarija BalicIngrid A MayerDavid A CameronEric P WinerJosé Juan Ponce LorenzoDiana LakeGunda Pristauz-TelsniggTufia C HaddadLois ShepherdHiroji IwataMatthew P GoetzFatima CardosoTiffany A TrainaDhanusha SabanathanUrs BreitensteinKerstin AckerlOtto Metzger FilhoKarin ZehetnerKadine SolomonSarra El-AbedKathy Puyana TheallDongrui Ray LuAmylou C DueckMichael GnantAngela M DeMichelePublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Despite observed rates of discontinuation in PALLAS, analyses suggest that the lack of significant iDFS difference between arms was not directly related to inadequate palbociclib exposure. However, the discontinuation rate illustrates the challenge of introducing novel adjuvant treatments, and the need for interventions to improve persistence with oral cancer therapies.
Keyphrases